JP2022520803A5 - - Google Patents

Info

Publication number
JP2022520803A5
JP2022520803A5 JP2021547189A JP2021547189A JP2022520803A5 JP 2022520803 A5 JP2022520803 A5 JP 2022520803A5 JP 2021547189 A JP2021547189 A JP 2021547189A JP 2021547189 A JP2021547189 A JP 2021547189A JP 2022520803 A5 JP2022520803 A5 JP 2022520803A5
Authority
JP
Japan
Prior art keywords
protein
dna
nucleic acid
itr
rep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021547189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520803A (ja
JP7644014B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018332 external-priority patent/WO2020168222A1/en
Publication of JP2022520803A publication Critical patent/JP2022520803A/ja
Publication of JP2022520803A5 publication Critical patent/JP2022520803A5/ja
Priority to JP2024064717A priority Critical patent/JP2024083567A/ja
Application granted granted Critical
Publication of JP7644014B2 publication Critical patent/JP7644014B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021547189A 2019-02-15 2020-02-14 閉端DNA(ceDNA)の産生におけるREPタンパク質活性の調節 Active JP7644014B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024064717A JP2024083567A (ja) 2019-02-15 2024-04-12 閉端DNA(ceDNA)の産生におけるREPタンパク質活性の調節

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806076P 2019-02-15 2019-02-15
US62/806,076 2019-02-15
PCT/US2020/018332 WO2020168222A1 (en) 2019-02-15 2020-02-14 Modulation of rep protein activity in closed-ended dna (cedna) production

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024064717A Division JP2024083567A (ja) 2019-02-15 2024-04-12 閉端DNA(ceDNA)の産生におけるREPタンパク質活性の調節

Publications (3)

Publication Number Publication Date
JP2022520803A JP2022520803A (ja) 2022-04-01
JP2022520803A5 true JP2022520803A5 (cg-RX-API-DMAC7.html) 2023-02-22
JP7644014B2 JP7644014B2 (ja) 2025-03-11

Family

ID=72045641

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547189A Active JP7644014B2 (ja) 2019-02-15 2020-02-14 閉端DNA(ceDNA)の産生におけるREPタンパク質活性の調節
JP2024064717A Pending JP2024083567A (ja) 2019-02-15 2024-04-12 閉端DNA(ceDNA)の産生におけるREPタンパク質活性の調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024064717A Pending JP2024083567A (ja) 2019-02-15 2024-04-12 閉端DNA(ceDNA)の産生におけるREPタンパク質活性の調節

Country Status (11)

Country Link
US (1) US20220127625A1 (cg-RX-API-DMAC7.html)
EP (1) EP3924491A4 (cg-RX-API-DMAC7.html)
JP (2) JP7644014B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210127935A (cg-RX-API-DMAC7.html)
CN (1) CN113454232B (cg-RX-API-DMAC7.html)
AU (1) AU2020221312A1 (cg-RX-API-DMAC7.html)
CA (1) CA3129321A1 (cg-RX-API-DMAC7.html)
IL (1) IL285415A (cg-RX-API-DMAC7.html)
MA (1) MA54958A (cg-RX-API-DMAC7.html)
SG (1) SG11202106491VA (cg-RX-API-DMAC7.html)
WO (1) WO2020168222A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
PE20220233A1 (es) * 2019-06-10 2022-02-07 Homology Medicines Inc Composiciones de virus adenoasociados para la transferencia del gen de arsa y metodos de uso de las mismas
MX2023001109A (es) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
MX2023003019A (es) * 2020-09-16 2023-05-08 Generation Bio Co Vectores de adn de extremo cerrado y usos de estos para expresar fenilalanina hidroxilasa (pah).
US20240091382A1 (en) * 2020-12-23 2024-03-21 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
TW202302858A (zh) * 2021-03-16 2023-01-16 威斯康辛校友研究基金會 治療糖尿病之胰島素基因療法
WO2023028440A2 (en) * 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Baculovirus expression system
CN114703203B (zh) * 2022-02-11 2024-08-06 上海渤因生物科技有限公司 杆状病毒载体及其用途
KR102737146B1 (ko) * 2023-07-10 2024-12-09 대한민국 신규 발현 벡터 및 이의 용도
CN122341729A (zh) * 2023-11-30 2026-07-03 赛诺菲 末端封闭的dna分子的纯化
US12509711B1 (en) * 2024-08-09 2025-12-30 Martin Williams System and process for in vivo manufacturing nanostructure-ended double-stranded covalently-closed linear DNA, the resulting molecules and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2596292C (en) * 1997-03-21 2012-05-22 Enzo Therapeutics, Inc. Vectors and viral vectors, and packaging cell lines for propagating same
CN1183257C (zh) * 1999-10-29 2005-01-05 宝生物工程株式会社 基因转移的方法
WO2007148971A2 (en) * 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
EP2545165B1 (en) * 2010-03-11 2020-07-29 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
WO2015137802A1 (en) * 2014-03-10 2015-09-17 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
IL261524B2 (en) * 2016-03-03 2023-10-01 Univ Massachusetts End-capped linear double-stranded DNA for non-viral gene transfer
MX2020001593A (es) * 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.

Similar Documents

Publication Publication Date Title
JP2022190081A5 (cg-RX-API-DMAC7.html)
US11834683B2 (en) High titer recombinant AAV vector production in adherent and suspension cells
EP3436051B1 (en) Column-based fully scalable raav manufacturing process
JP2022516004A5 (cg-RX-API-DMAC7.html)
JP2022549380A5 (cg-RX-API-DMAC7.html)
JP2023171525A (ja) Aavキメラ
JP2020532981A5 (cg-RX-API-DMAC7.html)
JP2012519008A5 (cg-RX-API-DMAC7.html)
JP2022524434A5 (cg-RX-API-DMAC7.html)
JP2019533803A5 (cg-RX-API-DMAC7.html)
JP2022542828A5 (cg-RX-API-DMAC7.html)
JP2022512621A5 (cg-RX-API-DMAC7.html)
HRP20192141T1 (hr) Genska terapija za retinitis pigmentosa
JP2020519284A5 (cg-RX-API-DMAC7.html)
JP2022525302A5 (cg-RX-API-DMAC7.html)
JP2025517628A5 (cg-RX-API-DMAC7.html)
JP2023520763A5 (cg-RX-API-DMAC7.html)
AU2021372262B2 (en) Process for enriching adeno-associated virus
JP2025029049A5 (cg-RX-API-DMAC7.html)
CN118460614A (zh) 一种腺相关病毒Cap蛋白的表达框
JP2024503895A5 (cg-RX-API-DMAC7.html)
WO2024078584A1 (zh) 腺相关病毒的衣壳蛋白编码基因改造方法
RU2021126774A (ru) Модуляция активности rep белка при получении днк с замкнутыми концами (зкднк)
WO2025171001A1 (en) Compositions and methods for improved production of aav viral vectors
HK40096825A (en) Method of modifying genes encoding capsid proteins of adeno-associated viruses